Bull
$3.96
Scenario price
$4.900
-0.136 (-2.78%)At close
Universe Pharmaceuticals Inc is a holding company primarily engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine drugs (TCMDs) products targeting the elderly. The Company’s products include chronic condition treatments and cold and flu medicines. The chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor. The cold and flu medicines primarily include Paracetamol Granule for children, Isatis Root Granule and Qiangli Pipa Syrup. The Company is also engaged in the sales of biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies.
Given the current price of $4.90 and the RSI of 36.176, which indicates that the stock is in the oversold territory, it may not be the best time to buy. However, the recent acquisition of Best Praise International for $10.75 million could provide long-term growth potential. The stock has shown volatility, trading between $2.00 and $11.00 over the past year, and has recently surged over 300% following the acquisition announcement. The main risk is the negative forward P/E of 0, indicating uncertainty in future earnings.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Biotech Stocks Surge with Significant Gains

Universe Pharma Acquires Patent Portfolio, Shares Surge

Universe Pharmaceuticals Acquires Best Praise International

Universe Pharmaceuticals Acquires Best Praise International for $10.75 Million

Universe Pharmaceuticals Acquires Patent Portfolio to Expand Business
Universe Pharmaceuticals Inc is a holding company primarily engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine drugs (TCMDs) products targeting the elderly. The Company’s products include chronic condition treatments and cold and flu medicines. The chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor. The cold and flu medicines primarily include Paracetamol Granule for children, Isatis Root Granule and Qiangli Pipa Syrup. The Company is also engaged in the sales of biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $4.90 and the RSI of 36.176, which indicates that the stock is in the oversold territory, it may not be the best time to buy. However, the recent acquisition of Best Praise International for $10.75 million could provide long-term growth potential. The stock has shown volatility, trading between $2.00 and $11.00 over the past year, and has recently surged over 300% following the acquisition announcement. The main risk is the negative forward P/E of 0, indicating uncertainty in future earnings.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.